COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 1117: Articles 11161-11170  | Next

Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions
Arsene, S., Couty, C., Faddeenkov, I., Go, N., Granjeon-Noriot, S., Smit, D., Kahoul, R., Illigens, B., Boissel, J.-P., Chevalier, A., Lehr, L., Pasquali, C., Kulesza, A.
10.1101/2021.11.09.21266145 — Posted: 2021-11-10
Genomic landscape of SARS-CoV-2 pandemic in Brazil suggests an external P.1 variant origin
Perico, C. P., De Pierri, C. R., Neto, G. P., Fernandes, D. R., Pedrosa, F. d. O., de Souza, E. M., Raittz, R. T.
10.1101/2021.11.10.21266084 — Posted: 2021-11-10
COVID-19 vaccinations: perceptions and behaviours in people with primary ciliary dyskinesia
Pedersen, E. S. L., Mallet, M. C., Lam, Y. T., Bellu, S., Cizeau, I., Copeland, F., Fernandez, T. L., Manion, M., Harris, A., Lucas, J. S., Santamaria, F., COVID-PCD patient advisory group, , Goutaki, M., Kuehni, C. E.
10.1101/2021.11.08.21266047 — Posted: 2021-11-10
Design of D-amino acids SARS-CoV-2 Main protease inhibitors using the cationic peptide from rattlesnake venom as a scaffold
Eberle, R. J., Gering, I., Tusche, M., Ostermann, P. N., Mueller, L., Adams, O., Schaal, H., Olivier, D. S., Amaral, M. S., Arni, R. K., Willbold, D., Coronado, M.
10.1101/2021.11.10.468025 — Posted: 2021-11-10
Characterization of the humoral immune response to BNT162b2 in elderly residents of long-term care facilities five to seven months after vaccination
Delbrueck, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E., Ciesek, S.
10.1101/2021.11.09.21266110 — Posted: 2021-11-10
Unexposed populations and potential COVID-19 burden in European countries
Chapman, L. A. C., Barnard, R. C., Russell, T. W., Abbott, S., van Zandvoort, K., Davies, N. G., Kucharski, A. J.
10.1101/2021.11.10.21266166 — Posted: 2021-11-10 Discussion: Onsite
Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting
Portal Celhay, C., Forleo-Neto, E., Eagan, W., Musser, B. J., Davis, J. D., Turner, K. C., Norton, T. D., Hooper, A. T., Hamilton, J. D., Pan, C., Mahmood, A., Baum, A., Kyratsous, C., Kim, Y., Parrino, J., Kampman, W., Roque-Guerrero, L., Stoici, R., Fatakia, A., Soo, Y., Geba, G. P., Kowal, B., DiCioccio, A. T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G. A., Yancopoulos, G. D., Weinreich, D. M., Study Investigators
10.1101/2021.11.09.21265912 — Posted: 2021-11-10
Mice infected with Mycobacterium tuberculosis are resistant to secondary infection with SARS-CoV-2
Rosas Mejia, O., Gloag, E., Li, J., Ruane-Foster, M., Claeys, T. A., Farkas, D., Farkas, L., Xin, G., Robinson, R.
10.1101/2021.11.09.467862 — Posted: 2021-11-10
ChAdOx1 n-COV-19 Vaccine Side Effects Among Health Care Workers in Trinidad and Tobago
Gopaul, C. D., Ventour, D., Thomas, D.
10.1101/2021.11.09.21264627 — Posted: 2021-11-10
Minimal in-school SARS-CoV-2 transmission with strict mitigation protocols at two independent schools in Nashville, TN
Peetluk, L. S., Rebeiro, P. F., Edwards, K. M., Banerjee, R., Mallal, S. A., Aronoff, D. M., Lipworth, L., Katz, S. E.
10.1101/2021.11.09.21266140 — Posted: 2021-11-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).